Arcturus Therapeutics Holdings Inc. (ARCT)

Market Cap	679.59M
Revenue (ttm)	264.47M
Net Income (ttm)	80.29M
Shares Out	26.60M
EPS (ttm)	3.00
PE Ratio	8.52
Forward PE	2.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	468,455
Open	25.71
Previous Close	25.44
Day's Range	25.13 - 26.17
52-Week Range	13.83 - 37.75
Beta	2.64
Analysts	Buy
Price Target	38.83 (+51.98%)
Earnings Date	Nov 8, 2023

About ARCT

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 170
• Stock Exchange: NASDAQ
• Ticker Symbol: ARCT

Analyst Forecast

According to 8 analysts, the average rating for ARCT stock is "Buy." The 12-month stock price forecast is $38.83, which is an increase of 51.98% from the latest price.

Price Target

$38.83

(51.98% upside)

Analyst Consensus: Buy